Comparative Analysis of CD4+ and CD8+ T Cell Infiltration and PD-L1 Expression

Overview

This study compares CD4+ and CD8+ T cell infiltration and PD-L1 expression in biopsy versus resection specimens of gastric and colorectal adenocarcinomas. Findings indicate that resection specimens exhibit significantly higher immune cell densities and PD-L1 expression.

Background

Understanding the immune microenvironment in gastric and colorectal adenocarcinomas is crucial. Biopsy specimens are often used for initial assessments, but their reliability in representing the tumor's immune landscape is uncertain.

Data Highlights

Key Findings

• Resection specimens of gastric adenocarcinoma showed significantly higher CD4+ and CD8+ T cell densities compared to biopsies (P<0.05).
• In colorectal adenocarcinoma, only CD8+ T cell density was significantly higher in resection specimens (P=0.0446).
• CD4+ T cell density was positively correlated with CA19-9 levels in gastric cancer (R=0.523, P=0.026).
• CD4+ T cells negatively correlated with Ki-67 in colorectal cancer (R=-0.370, P=0.019).
• CD4+/CD8+ ratios were positively correlated at tumor center and invasive margin in both cancer types.

Clinical Implications

The findings indicate differences in immune cell infiltration between biopsy and resection specimens.

Conclusion

This study highlights the limitations of biopsy specimens in reflecting the immune landscape of gastric and colorectal adenocarcinomas.

Related Resources & Content

1. Gastric Cancer — Significance of PD-1 Expressing CD8 T-Cells in the Context of Gastric Cancer, 2023
2. Gastric Cancer — Enhanced Scoring of PD-L1 in Gastric Carcinoma, 2021
3. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update, 2025
4. Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement, 2020
5. Journal of Gastrointestinal Surgery — Dendritic Cell Involvement in Barrett's Esophagus and the Development of Esophageal Adenocarcinoma
6. Gastric Cancer — Simultaneous Targeting of PD-1/PD-L1, Lag-3, and Tim-3 Pathways Enhances Antitumor Immune Responses in Coculture Models of Gastric Cancer T Cells
7. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update | Journal of Clinical Oncology
8. Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists
9. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology - PubMed
10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer - PMC
11. Spatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers - PMC
12. Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study - PMC
13. A biopsy-based Immunoscore in patients with treatment-naïve resectable gastric cancer - Tanya T. D. Soeratram, Isis Beentjes, Jacqueline M. P. Egthuijsen, Aart Mookhoek, Marilyne M. Lange, Elma Meershoek-Klein Kranenbarg, Henk H. Hartgrink, Cornelis J. H. van de Velde, Bauke Ylstra, Hanneke W. M. van Laarhoven, Nicole C. T. van Grieken, 2024
14. Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement - PMC
15. Comparative Analysis of Tumor‐Immune Microenvironment Diversity Among Biopsy, Resection, and Metastatic Colorectal Cancer Specimens - PMC
16. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study - PubMed
17. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial | Journal of Clinical Oncology
18. Efficacy of immunochemotherapy (ICT) in patients (pts) with metastatic gastric cancer (mGC) in context of ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and PD-L1 expression: Results of the meta-analysis. | Journal of Clinical Oncology